PCN355 DO PAYER AND PRESCRIBER ENDPOINT PREFERENCES ALIGN?: IMMUNE CHECKPOINT INHIBITORS IN NON-SMALL CELL LUNG CANCER

Abstract

Authors

Y. Privolnev B. Adler

Full Text Cite This Article
Back to Volume 22, Supplemental S3
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×